Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis

Clinical and Experimental Rheumatology

Volumn 29, Issue 3, 2011, Pages 547-550

  Molena, B ^a   Sfriso, P ^a   Oliviero, F ^a   Pagnin, E ^a   Teramo, A ^a   Lunardi, F ^a   Stramare, R ^a   Scanu, A ^a   Nardacchione, R ^b   Rubaltelli, L ^a   Calabrese, F ^a   Punzi, L ^a   Fiocco, Ugo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Abano Terme Hospital   (Italy)

Author keywords

Colony stimulating factor 1; Diffuse pigmented villonodular synovitis; Persistent gonoarthritis; Real time polymerase chain reaction; Synovial gene expression

Indexed keywords

COLONY STIMULATING FACTOR 1; MESSENGER RNA; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JOINT BIOPSY; KNEE ARTHRITIS; KNEE ARTHROSCOPY; KNEE INJURY; MALE; OUTPATIENT CARE; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ARTHRITIS; BIOPSY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; INJURY; KNEE MENISCUS; METABOLISM; MIDDLE AGED; PATHOLOGY; SYNOVIUM;

ADULT; ARTHRITIS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MENISCI, TIBIAL; MIDDLE AGED; RNA, MESSENGER; SYNOVIAL MEMBRANE; SYNOVITIS, PIGMENTED VILLONODULAR;

EID: 80052058228     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. JAFFE H.L., LICHTENSTEIN L., SUTRO C.J.: Pigmented villonodularis synovitis: Bursitis and tenosynovitis. Arch Pathol 1941; 31: 731-765
2. BYERS P.D., COTTON R.E., DEACON O.W. et al.: The diagnosis and treatment of pigmented villonodular synovitis. J Bone Joint Surg Br 1968; 50: 290-305.
3. YOSHIDA W., UZUKI M., KUROSE A. et al.: Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 2003; 34: 65-73.
4. BERGER I. WECKAUF H. HELMCHEN B et al.: Rheumatoid arthritis and pigmented villonodular synovitis: Comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathology 2005; 46: 490-497
5. FINIS K., SULTMANN H., RUSCHHAUPT M. et al.: Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches. Arthritis Rheum 2006; 54: 1009-1019
6. KOMANO Y., NANKI T., HAYASHIDA K., TANIGUCHI K., MIYASAKA N.: Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006; 8: R152.
7. GELDYYEV A., KOLEGANOVA N., PIECHA G. et al.: High expression level of bone degrading proteins as a possible inducer of osteolytic features in pigmented villonodular synovitis. Cancer Lett 2007; 255: 2785-2793
8. FORSYTH R.G., DE BOECK G., BAELDE J.J. et al.: CD33&bsup;+&esup; CD14&bsup;-&esup; phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res 2009; 24: 70-77
9. BRANDAL P., BJERKEHAGEN B., HEIM S.: Molecular cytogenetic characterization of tenosynovial giant cell tumors. Neoplasia 2004; 6: 578-583
10. MENDENHALL W.M., MENDENHALL C.M., REITH J.D., SCARBOROUGH M.T., GIBBS C.P., MENDENHALL N.P.: Pigmented villonodular synovitis. Am J Clin Oncol 2006; 29: 548-550
11. WEST B.R., RUBIN B.P., MILLER M.A. et al.: Landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103: 690-695
12. SHERR C.J., RETTENMIER C.W., SACCA R., ROUSSEL M.F., LOOK A.T., STANLEY E.R.: The c-fms protooncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985; 41: 665-676
13. ROTH P., STANLEY E.R.: The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol 1992; 181: 141-167
14. CHITU V., STANLEY ER: Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39-48.
15. PIXLEY F.J., STANLEY E.R.: CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol 2004; 14: 628-638
16. ZINS K., ABRAHAM D., SIOUD M., AHARINOAD S.: Colon cancer cell-derived tumor necrosis factor-α mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007; 67: 1038-1045
17. FIOCCO U., SFRISO P., LUNARDI F. et al.: Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis. Autoimmun Rev 2010; 9: 780-784
18. ALTMAN D.G.: Practical statistics for medical research. London: Chapman and Hall, 1991: 211-212
19. NAKANO K., OKADA Y., SAITO K. et al.: Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology 2007; 46: 597-603.
20. PANIAGUA R.T., CHANG A., MARIANO M.M. et al.: c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther 2010; 12: R32.
21. MOLLER E., MANDAHL N., MERTENS F., PANAGOPOULOS 1: Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer 2008; 47: 21-25
22. CUPP J.S., MILLER M.A., MONTGOMERY K.D. et al.: Translocation and expression of CSFl in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 2007; 31: 970-976
23. HUANG H.Y., WEST R.B., TZENG C.C. et al.: Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clin Cancer Res 2008; 14: 6023-6032
24. OSTER W., LINDEMANN A., HORN S., MERTELSMANN R., HERRMANN F.: Tumor necrosis factor (TNF)-α but not TNF-β induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. Blood 1987; 70: 1700-1703
25. BRANCH D.R., TURNER A.R., GUILBERT U.: Synergistic Stimulation of Macrophage Proliferation by the Monokines Tumor Necrosis Factor-Alpha and Colony-Stimulating Factor 1. Blood 1989; 73: 307-311
26. YAO Z., LI P., ZHANG Q. et al: Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006; 281: 11846-11855
27. KOMANO Y., NANKI T., HAYASHIDA K., TANIGUCHI K., MIYASAKA N.: Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006; 8: R152.
28. KITAURA H., ZHOU P., KIM H.J., NOVACK D.V., ROSS F.P., TEITELBAUM S.L.: M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005; 115: 3418-3427
29. DOUGLASS T.G., DRIGGERS L., ZHANG J.G. et al.: Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies. Int Immunopharmacol 2008; 8: 1354-1376
30. ONO M.: Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-1506
31. EUBANK T.D., GALLOWAY M., MONTAGUE C.M., WALDMAN W.J., MARSH C.B.: M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 2003; 171: 2637-2643
32. CURRY J.M., EUBANK T.D., ROBERTS R.D. et al.: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 2008; 3: e3405.
33. DEWAR A.L., CAMBARERI A.C., ZANNETTINO A.C. et al.: Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-3132
34. GUO J., MARCOTTE P.A., McCALL J.O. et al.: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006; 5: 1007-1013
35. KUBOTA Y., TAKUBO K., SHIMIZU T. et al.: M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206: 1089-1102
36. BROWNLOW N., MOL C., HAYFORD C., GHAEMMAGHAMI S., DIBB N.J.: Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009; 23: 590-594
37. ANDO W., HASHIMOTO J., NAMPEI A. et al.: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006; 24: 274-282
38. EL HAJJ DIB I., GALLET M., MENTAVERRI R., SÉVENET N., BRAZIER M., KAMEL S.: Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006; 551: 27-33.
39. PANIAGUA R.T., SHARPE O., HO P.P. et al.: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006; 116: 2633-2642
40. D'AURA SWANSON C., PANIAGUA R.T., LINDSTROM T.M., ROBINSON W.H.: Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 317-324
41. SCOTT D.A., AQUILA B.M., BEBERNITZ G.A. et al.: Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer. Bioorg Med Chem Lett 2008; 1: 4794-4797
42. PATEL S., PLAYER M.R.: Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 2009; 9: 599-610.
43. SAGLIO G., KIM D.W., ISSARAGRISIL S. et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259
44. BLAY J.Y., EL SAYADI H., THIESSE P., GARRET J., RAY-COQUARD 1: Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19: 821-822